PTEN and neoplasm: Moreover, concomitantly with the ERG transcriptional reversion, treatment with GSK343 caused in ERG/PTEN mice a striking reduction of the tumor burden, estimated as total prostate volume, compared to vehicle-treated control mice (Fig. 6l).